Cargando…
Doxorubicin-Mediated Bone Loss in Breast Cancer Bone Metastases Is Driven by an Interplay between Oxidative Stress and Induction of TGFβ
Breast cancer patients, who are already at increased risk of developing bone metastases and osteolytic bone damage, are often treated with doxorubicin. Unfortunately, doxorubicin has been reported to induce damage to bone. Moreover, we have previously reported that doxorubicin treatment increases ci...
Autores principales: | Rana, Tapasi, Chakrabarti, Anwesa, Freeman, Michael, Biswas, Swati |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813496/ https://www.ncbi.nlm.nih.gov/pubmed/24205081 http://dx.doi.org/10.1371/journal.pone.0078043 |
Ejemplares similares
-
Correction: Doxorubicin-Mediated Bone Loss in Breast Cancer Bone Metastases Is Driven by an Interplay between Oxidative Stress and Induction of TGFβ
por: Rana, Tapasi, et al.
Publicado: (2013) -
Anti-Transforming Growth Factor ß Antibody Treatment Rescues Bone Loss and Prevents Breast Cancer Metastasis to Bone
por: Biswas, Swati, et al.
Publicado: (2011) -
The Role of TGF-β in Bone Metastases
por: Trivedi, Trupti, et al.
Publicado: (2021) -
Role of TGF-β in breast cancer bone metastases
por: Chiechi, Antonella, et al.
Publicado: (2013) -
Excess TGF-β mediates muscle weakness associated with bone metastases in mice
por: Waning, David L., et al.
Publicado: (2015)